A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy Versus Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-Myeloablative Allogeneic Stem Cell Transplant for Patients with Multiple Myeloma

Pts must be less than or equal to 70 years of age with Karnofsky scores greater than or equal to 70. Pts must meet Durie and Salmon criteria for initial diagnosis of multiple myeloma. Pts must have symptomatic multiple myeloma requiring treatment. Pts who have received at least three cycles of systemic therapy and who are within 2-9 months of initiation of the initial therapy. Pts must be able to receive high-dose melphalan between 2 and 8 weeks after the initiation of mobilization therapy whether delivered at the transplant center or at a referring center. Pts must have adequate organ function per the protocol. Pts must have available an autograft meeting the specifications outlined in the protocol unless it is known prior to enrollment that they will receive an allogeneic transplant after their initial autologous transplant. Pts with a consenting, eligible HLA-matched sibling must have an autograft meeting the specifications outlined in the protocol.